G 2/21: how to support inventive steps in patentability

Post-published evidence can be crucial to establishing patentability. G 2/21, the European Patent Office (EPO)’s referral to the Enlarged Board of Appeal (EBA) on the question of whether post-published evidence can be used to support the concept of “inventive step”.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Careers

Cooley Asia transactions duo make rival firm move

23 June 2026 The pair bring a strong track record advising life sciences companies on licensing, collaboration and commercialisation agreements, with a particular focus on cross-border biotech transactions.

Biotechnology

Insilico lands potential $2.5bn AI biotech partnership

22 June 2026 The partnership, announced at BIO 2026, marks the largest Asia-Pacific partnership by potential value that the AI-driven drug discovery company has secured to date.

Asia

‘Blatant imitation’: Indian court blocks copycat pharma branding

22 June 2026 The court granted Blue Cross Laboratories a permanent injunction after finding that a rival product’s mark and packaging closely mirrored its own.

More features

European court backs AstraZeneca unit in blood cancer combo dispute

Boehringer Ingelheim adds ex-Teva executive to patent team

AI, anxiety, and antibodies: The issues dominating life sciences

Healthcare leads sweeping AI partnership in Singapore

WATCH: Interview with Mythili Markowski, director at Regeneron

Patent office fee increases: What applicants must know

UK patent office adopts EPO standards for AI inventions

Closing the women's health gap offers ‘benefits for all’

G 2/21: how to support inventive steps in patentability

More on this story

Editor's picks

Editor's picks

More features